Meeting
2023 ASCO Genitourinary Cancers Symposium
A phase 1, open-label trial to evaluate feasibility and safety of intramural injection of belzupacap sarotalocan (AU-011) in non-muscle–invasive bladder cancer (NMIBC).
Authors
Seth P. Lerner
Baylor College of Medicine, Houston, TX
Seth P. Lerner , Trinity Bivalacqua , Isaac Yi Kim , Carrie Murray , Cadmus Collins Rich , Piyush K. Agarwal , Neal D. Shore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05483868
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS596)
DOI
10.1200/JCO.2023.41.6_suppl.TPS596
Abstract #
TPS596
Poster Bd #
P19
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).
First Author: Naval Guastad Daver
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase I, open-label, dose-finding study of fatty acid synthase (FASN) inhibitor TVB-2640 administered in combination with enzalutamide (Enza) in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Pier VItale Nuzzo
Poster
2023 ASCO Annual Meeting
Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.
First Author: Joseph J. Sacco
Poster
2022 ASCO Annual Meeting
A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis.
First Author: Haris Ali